Announcement • Mar 30
Vetoquinol SA, Annual General Meeting, May 20, 2026 Vetoquinol SA, Annual General Meeting, May 20, 2026. Announcement • Mar 27
Vetoquinol SA Proposes Cash Dividend Based on these results, the Board of Directors of Vetoquinol SA will propose to the Annual General Meeting of Shareholders on May 20, 2026, the payment of a dividend of €0.93 per share. Reported Earnings • Sep 17
First half 2025 earnings released: EPS: €2.13 (vs €2.01 in 1H 2024) First half 2025 results: EPS: €2.13 (up from €2.01 in 1H 2024). Revenue: €257.6m (down 2.6% from 1H 2024). Net income: €25.1m (up 5.3% from 1H 2024). Profit margin: 9.7% (in line with 1H 2024). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Pharmaceuticals industry in France. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 28
Upcoming dividend of €0.89 per share Eligible shareholders must have bought the stock before 04 June 2025. Payment date: 06 June 2025. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of French dividend payers (5.4%). Lower than average of industry peers (3.9%). Declared Dividend • Apr 14
Dividend increased to €0.89 Dividend of €0.89 is 4.7% higher than last year. Ex-date: 4th June 2025 Payment date: 6th June 2025 Dividend yield will be 1.2%, which is lower than the industry average of 3.9%. Payout Ratios Payout ratio: 21%. Cash payout ratio: 12%. Reported Earnings • Mar 23
Full year 2024 earnings released Full year 2024 results: Revenue: €539.2m (up 1.9% from FY 2023). Net income: €58.7m (up 5.7% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Pharmaceuticals industry in France. Valuation Update With 7 Day Price Move • Mar 21
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €85.60, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in France. Total loss to shareholders of 36% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €106 per share. Price Target Changed • Jan 31
Price target decreased by 8.4% to €93.43 Down from €102, the current price target is an average from 7 analysts. New target price is 32% above last closing price of €71.00. Stock is down 31% over the past year. The company is forecast to post earnings per share of €4.49 for next year compared to €4.70 last year. Announcement • Jan 17
Vetoquinol SA, Annual General Meeting, Mar 20, 2025 Vetoquinol SA, Annual General Meeting, Mar 20, 2025. Board Change • Jan 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 5 highly experienced directors. Independent Director Anne-Marie Graffin was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 28
Upcoming dividend of €0.85 per share Eligible shareholders must have bought the stock before 04 June 2024. Payment date: 06 June 2024. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of French dividend payers (5.2%). Lower than average of industry peers (3.8%). Declared Dividend • Apr 23
Dividend increased to €0.85 Dividend of €0.85 is 6.3% higher than last year. Ex-date: 4th June 2024 Payment date: 6th June 2024 Dividend yield will be 0.9%, which is lower than the industry average of 3.9%. Reported Earnings • Mar 24
Full year 2023 earnings released Full year 2023 results: Revenue: €529.3m (down 1.9% from FY 2022). Net income: €55.6m (up 16% from FY 2022). Profit margin: 11% (up from 8.9% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 4.6% growth forecast for the Pharmaceuticals industry in France. Announcement • Mar 23
Vetoquinol SA Proposes Dividend The Board of Directors of Vetoquinol SA announced it will propose a dividend of €0.85 per share at the Annual General Meeting on May 28, 2024. Buy Or Sell Opportunity • Jan 25
Now 25% undervalued Over the last 90 days, the stock has risen 28% to €101. The fair value is estimated to be €135, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.3% over the last 3 years. Earnings per share has grown by 25%. Revenue is forecast to grow by 8.1% in 2 years. Earnings are forecast to grow by 5.8% in the next 2 years. Price Target Changed • Oct 30
Price target decreased by 7.3% to €100 Down from €108, the current price target is an average from 7 analysts. New target price is 27% above last closing price of €78.80. Stock is down 6.3% over the past year. The company is forecast to post earnings per share of €4.80 for next year compared to €4.06 last year. Reported Earnings • Mar 24
Full year 2022 earnings released Full year 2022 results: Revenue: €539.8m (up 3.6% from FY 2021). Net income: €48.0m (down 24% from FY 2021). Profit margin: 8.9% (down from 12% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in France. Price Target Changed • Nov 16
Price target decreased to €120 Down from €130, the current price target is an average from 6 analysts. New target price is 38% above last closing price of €87.00. Stock is down 41% over the past year. The company is forecast to post earnings per share of €4.88 for next year compared to €5.31 last year. Price Target Changed • Oct 14
Price target decreased to €120 Down from €130, the current price target is an average from 6 analysts. New target price is 41% above last closing price of €85.40. Stock is down 40% over the past year. The company is forecast to post earnings per share of €4.89 for next year compared to €5.31 last year. Reported Earnings • Sep 18
First half 2022 earnings released: EPS: €1.81 (vs €3.06 in 1H 2021) First half 2022 results: EPS: €1.81 (down from €3.06 in 1H 2021). Revenue: €270.8m (up 6.0% from 1H 2021). Net income: €21.4m (down 41% from 1H 2021). Profit margin: 7.9% (down from 14% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in France. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Price Target Changed • Sep 16
Price target decreased to €135 Down from €152, the current price target is an average from 6 analysts. New target price is 57% above last closing price of €86.00. Stock is down 34% over the past year. The company is forecast to post earnings per share of €5.37 for next year compared to €5.31 last year. Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment deteriorated over the past week After last week's 24% share price decline to €86.00, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 19x in the Pharmaceuticals industry in France. Total returns to shareholders of 48% over the past three years. Upcoming Dividend • May 27
Upcoming dividend of €0.80 per share Eligible shareholders must have bought the stock before 03 June 2022. Payment date: 07 June 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of French dividend payers (5.0%). Lower than average of industry peers (3.0%). Buying Opportunity • Apr 15
Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 9.6%. The fair value is estimated to be €168, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings is also forecast to grow by 4.1% per annum over the same time period. Buying Opportunity • Mar 02
Now 20% undervalued Over the last 90 days, the stock is up 2.0%. The fair value is estimated to be €163, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% per annum over the last 3 years. Earnings per share has declined by 7.8% per annum over the last 3 years. Buying Opportunity • Feb 04
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be €161, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% per annum over the last 3 years. Earnings per share has declined by 7.8% per annum over the last 3 years. Price Target Changed • Oct 15
Price target increased to €139 Up from €126, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of €141. Stock is up 64% over the past year. Board Change • Sep 26
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. Independent Director Elisabeth Pacaud was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 03
First half 2021 earnings released The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €255.3m (up 30% from 1H 2020). Net income: €36.2m (up 141% from 1H 2020). Profit margin: 14% (up from 7.7% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings. Price Target Changed • Jul 31
Price target increased to €123 Up from €114, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of €122. Stock is up 78% over the past year. Major Estimate Revision • Jul 31
Consensus EPS estimates increase to €4.16 The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from €481.9m to €506.0m. EPS estimate increased from €3.60 to €4.16 per share. Net income forecast to grow 184% next year vs 18% decline forecast for Pharmaceuticals industry in France. Consensus price target up from €114 to €123. Share price rose 18% to €122 over the past week. Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment improved over the past week After last week's 18% share price gain to €122, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 31x in the Pharmaceuticals industry in France. Total returns to shareholders of 125% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €104 per share. Upcoming Dividend • May 28
Upcoming dividend of €0.50 per share Eligible shareholders must have bought the stock before 04 June 2021. Payment date: 08 June 2021. Trailing yield: 0.5%. Lower than top quartile of French dividend payers (3.8%). Lower than average of industry peers (3.4%). Price Target Changed • Apr 08
Price target increased to €109 Up from €99.20, the current price target is an average from 4 analysts. New target price is 6.7% above last closing price of €102. Stock is up 98% over the past year. Reported Earnings • Apr 02
Full year 2020 earnings released The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €427.5m (up 8.0% from FY 2019). Net income: €19.2m (down 33% from FY 2019). Profit margin: 4.5% (down from 7.2% in FY 2019). Is New 90 Day High Low • Feb 12
New 90-day high: €95.60 The company is up 7.0% from its price of €89.20 on 13 November 2020. The French market is also up 7.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €76.64 per share. Price Target Changed • Feb 03
Price target raised to €99.20 Up from €92.60, the current price target is an average from 5 analysts. The new target price is 11% above the current share price of €89.00. As of last close, the stock is up 51% over the past year. Major Estimate Revision • Jan 23
Analysts update estimates The 2020 consensus earning per share (EPS) estimate was lowered from €3.03 to €2.52. Revenue estimate was approximately flat at €432.4m. Net income is expected to grow by 17% next year compared to 12% growth forecast for the Pharmaceuticals industry in France. The consensus price target increased from €92.60 to €97.00. Share price stayed mostly flat at €89.40 over the past week. Announcement • Jan 19
Orion Animal Health and Vetoquinol Expand Their Collaboration with New Distribution Agreements The U.S. Food and Drug Administration FDA granted approval for Orion’s Clevor®, an eye drop indicated for the induction of vomiting in dogs, in June 2020. Under the terms of the related agreement, Vetoquinol will have the right to sell and market Clevor® (ropinirole) in the USA. On August 1, 2020, Vetoquinol acquired the rights for the Drontal® and Profender® products in the EU and the UK. Effective January 1, 2021, Orion will have the right to sell and market Vetoquinol’s Drontal® and Profender® products in Finland, Hungary and Romania. Drontal® product range is used for the treatment and control of internal parasites in cats and dogs and Profender® for the treatment and control of internal parasites in cats. These new distribution agreements expand the current collaboration between the two companies under which Vetoquinol has been distributing Orion Animal Health’s sedative products in several European countries since February 2015. Is New 90 Day High Low • Jan 19
New 90-day high: €90.40 The company is up 7.0% from its price of €84.80 on 21 October 2020. The French market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €77.38 per share. Is New 90 Day High Low • Nov 10
New 90-day high: €90.00 The company is up 26% from its price of €71.20 on 11 August 2020. The French market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €66.58 per share. Is New 90 Day High Low • Oct 23
New 90-day high: €86.60 The company is up 24% from its price of €69.80 on 24 July 2020. The French market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €74.14 per share. Is New 90 Day High Low • Oct 06
New 90-day high: €73.60 The company is up 9.0% from its price of €67.80 on 08 July 2020. The French market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €76.56 per share. Announcement • Sep 02
Vetoquinol Ordinary Shares to Be Deleted from Other OTC Vetoquinol SA Ordinary Shares (France) will be deleted from other OTC on September 01, 2020 due to inactive security. 
